@AaronGoodman33 Typical cytomorphology is characterized by “blasts” with hand mirror (red arrow, cytoplasm to the side) or pearl necklace (green arrow, small cytoplasmic vacuoles around nucleus) appearance #bpdcn#hemepath#RareDisease#WHOHEME 1/
@AaronGoodman33 Skin and lymph node are most common extramedullary sites of involvement. Skin infiltrate is usually dermal with an appreciable “grenz zone” (uninvolved band b/w dermis and epidermis).. Lymph node typically has diffuse or paracortical involvement #hemepath#WHOHEME#BPDCN
One of the difficult aspects of #hemepath training is time management in a high-paced/demanding environment & the ability to multitask effectively while learning a difficult discipline. Every yr I offer our fellows helpful tips I’ve learned so far 🧵👇🏻More tips welcome,pls add 1/
Get rid of paper…
Don’t do anything twice
Take ownership of your cases… they are just as much yours as they are your faculty’s
Just another ordinary day at #hemepathMDA … 🤯
60-70 y/o woman
To all brave #hemepath aficionados how would you classify this case?
Poll and individual high quality images below. Pls comment if you’re feeling particularly brave today, let’s talk new #WHO 😎
The story of 1 day in the life of a #hematopathologist… I’m too exhausted to make a fancy educational thread but here are some amazing 🔬 pics for your viewing pleasure. I diagnosed all cases in one day 🤯 only at @MDAndersonNews Happy almost weekend people 🥂 #hemepath 🧵 1/n
Myeloproliferative neoplasm w/ concurrent BCR::ABL1 and JAK2 V617F ..the megekaryocyte morphology is clue to something beyond CML #mpnsm#PathOutPic 2/
BPDCN with perfect so-called “hand mirror” (red) and “pearl necklace” (black) morphology #BPDCN#PathOutPic 3/
WT1 mutations are present in ~7% of de novo AML, are typically Lof mutation involving exons 7-9 of the gene. They frequently (~15%) co-occur w/ NPM1mut & have detrimental impact in this setting, shown by @AkEisfeld and colleagues in bit.ly/3eWQtXw@LeukemiaJnl
We studies a cohort of de novo NPM1-mut AML. 7% had concurrent WT1 mutations at baseline. 22% (15/67) relapsed; 4 (27%) with newly acquired Lof WT1-mut. Illustrated by @furudateken